Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD Access the segment here ISELIN, N.J., Jan.

Pravin U. Dugel, MD, Ocular’s Executive Chairman, President and CEO, will provide an update regarding the enrollment status of SOL-R, the Company’s second registrational trial of AXPAXLI™ for the ...

From redness to gradual loss of vision to constant irritation, here are the early warning signs of eye diseases that should ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in ...

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

An announcement from Opthea Limited ( ($AU:OPT) ) is now available. Opthea Limited announced the publication of its Phase 1b ...

The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving ...

Opyl has entered a joint venture with X Firm to market its TrialKey platform in key markets, while Dimerix has inked another ...

A recent study found that the triple-layer sign (TLS) obtained on optical coherence tomography has high sensitivity and ...

Lenvatinib is under clinical development by AiViva BioPharma and currently in Phase II for Diabetic Macular Edema.